Targeting IKK/NF-kB for anti-ageing
- Detailed Technology Description
- None
- *Abstract
-
Aging is characterized by the progressive erosion of functional reserve in all organ systems. This places the elderly at increased risk of numerous debilitating diseases, for example cardiovascular disease, dementia, bone fractures and cancer. Demographics indicate that the number of individuals >65 will double in the next 25 years. Therefore identifying strategies to prevent loss of functional reserve is essential for maintaining the health of our aging population. IKK/NF-kB transcriptional activation is implicated in numerous debilitating disease processes including arthritis, inflammatory bowel disease, cachexia, muscular dystrophy, diabetes and cancer. Blocking IKK/NF-kB activation using a novel peptide inhibitor (NBD) or a small molecule inhibitor (Compound A) yields dramatic therapeutic effects in murine models of muscular dystrophy, inflammatory bowel disease, arthritis, multiple sclerosis and bone loss. NF-kB activation is also implicated as a driving force of cellular senescence. Furthermore, NF-kB has been demonstrated to be activated in a variety of tissues from aged mammals relative to young animals. These observations suggest the possibility of a causal role for IKK/NF-kB pathways in degenerative processes associated with aging and the potential to preserve functional reserve by inhibiting this pathway. Non Provisional and PCT Patent Applications Filed
- *Principal Investigator
-
Name: Laura Niedernhofer
Department: Med-Microbiology and Molecular Genetics
Name: Paul Robbins
Department: Med-Microbiology and Molecular Genetics
- Country/Region
- USA
For more information, please click Here
